Will mezigdomide find its place in the T-cell redirecting treatment landscape for relapsed multiple myeloma?
Affiliations & Notes
Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, 10066, United States of America
Article Info
Publication History:
Published June 17, 2026
DOI: 10.1016/S0140-6736(26)01199-2 External LinkAlso available on ScienceDirect External Link
Copyright: © 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.
The treatment landscape for relapsed or refractory multiple myeloma is rapidly evolving with the introduction of T-cell redirecting therapies.1–3 Recent randomised clinical trials have shown the superiority of anti-B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T-cell therapies and bispecific antibodies over standard-of-care regimens when used in earlier lines of therapy, leading to regulatory approvals around the world. However, access to these therapies might be restricted due to the need for specialised care and logistical considerations. Despite these unprecedented results, patients still relapse, underscoring the need for additional effective treatment strategies.
References
1.
Costa, LJ ∙ Bahlis, NJ ∙ Perrot, A ∙ et al., and the MajesTEC-3 Trial Investigators
Teclistamab plus daratumumab in relapsed or refractory multiple myeloma
N Engl J Med. 2026; 394:739-752
2.
San-Miguel, J ∙ Dhakal, B ∙ Yong, K ∙ et al.
Cilta-cel or standard care in lenalidomide-refractory multiple myeloma
N Engl J Med. 2023; 389:335-347
3.
Touzeau, C ∙ Mina, R ∙ Quach, H ∙ et al., and the MajesTEC-9 Trial Investigators
Teclistamab in multiple myeloma with one to three previous lines of therapy
N Engl J Med. 2026;
published online May 29. https://doi.org/10.1056/NEJMoa2603870
4.
Dimopoulos, MA ∙ Schjesvold, F ∙ Fu, C ∙ et al.
Mezigdomide, carfilzomib, and dexamethasone versus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma (SUCCESSOR-2): a phase 3, open-label, randomised controlled trial
Lancet. 2026;
published online June 14. https://doi.org/10.1016/S0140-6736(26)01088-3
5.
Richardson, PG ∙ Trudel, S ∙ Popat, R ∙ et al., and the CC-92480-MM-001 Study Investigators
Mezigdomide plus dexamethasone in relapsed and refractory multiple myeloma
N Engl J Med. 2023; 389:1009-1022
6.
Rodriguez-Otero, P ∙ Ailawadhi, S ∙ Arnulf, B ∙ et al.
Ide-cel or standard regimens in relapsed and refractory multiple myeloma
N Engl J Med. 2023; 388:1002-1014
7.
Avet-Loiseau, H ∙ Davies, FE ∙ Samur, MK ∙ et al.
International Myeloma Society/International Myeloma Working Group consensus recommendations on the definition of high-risk multiple myeloma
J Clin Oncol. 2025; 43:2739-2751
8.
Shi, Q ∙ Paiva, B ∙ Pederson, LD ∙ et al., and the International Independent Team for Endpoint Approval of Myeloma Minimal Residual Disease (i2TEAMM) Group
Minimal residual disease-based end point for accelerated assessment of clinical trials in multiple myeloma: a pooled analysis of individual patient data from multiple randomized trials
J Clin Oncol. 2025; 43:1289-1301